BridgeMD
GLYCOGEN RESPONSE TO ENZYME REPLACEMENT THERAPY IN POMPE DISEASE
EU CTIS ID: 2023-508000-37-01
What this study is testing
The objective of this trial it to characterize how muscle glycogen is affected by enzyme replacement therapy in treatment naïve patients with Pompe Disease.
- Therapeutic use (Phase IV)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- Subjects with genetically verified Late-onset Pompe Disease
- Age ≥18
- Naïve to enzyme replacement therapy
You likely can't join if
- Ferrous objects in or around the body
- Pacemaker or other implanted electronic devices
- Claustrophobia
- Inability to understand the purpose of the trial or corporate for the conduction of the experiments
- Participation in other trials that may interfere with the results
- Competing conditions at risk of compromising the results of the study, evaluated by the investigator
See the full eligibility criteria
- Subjects with genetically verified Late-onset Pompe Disease
- Age ≥18
- Naïve to enzyme replacement therapy
- Ferrous objects in or around the body
- Pacemaker or other implanted electronic devices
- Claustrophobia
- Inability to understand the purpose of the trial or corporate for the conduction of the experiments
- Participation in other trials that may interfere with the results
- Competing conditions at risk of compromising the results of the study, evaluated by the investigator
- Pregnancy
The study team makes the final eligibility decision.
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18-64 years, 65+ years. The study team makes the final eligibility decision.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.